📊 CSDX Key Takeaways
Is Cs Diagnostics Corp.. (CSDX) a Good Investment?
CS Diagnostics exhibits severe operational dysfunction with revenue of only $94.2K, negative operating cash flow of -$528K, and implausible balance sheet metrics (499.4M in assets with 1.6K liabilities) suggesting data integrity issues. The company demonstrates unprofitable cash generation despite reported net margins of 34.1%, indicating the operating profitability is illusory and the business model is fundamentally broken.
Fundamentals appear extremely weak despite a reported positive net margin, because the company generates only minimal revenue relative to an enormous stated asset and equity base and has essentially no cash on hand. Negative operating cash flow, missing key line items, and a highly unusual balance sheet profile raise serious concerns about earnings quality, asset quality, and the reliability of underlying business performance.
Why Buy Cs Diagnostics Corp.. Stock? CSDX Key Strengths
- Strong reported net profit margin of 34.1%
- Zero debt and strong stated stockholders equity position
- Positive reported operating income of $32.1K
- Reported operating and net income were positive in the latest period
- Balance sheet shows almost no reported liabilities or leverage
- Reported equity base is very large relative to liabilities
CSDX Stock Risks: Cs Diagnostics Corp.. Investment Risks
- Severe negative free cash flow of -$528K contradicts profitability claims, indicating cash burn despite reported profits
- Extremely limited revenue base of $94.2K indicates minimal business operations or severe business decline
- Implausible balance sheet with $499.4M assets against $1.6K liabilities and $13 cash suggests data quality issues or accounting abnormalities
- Zero insider activity in last 90 days indicates lack of management confidence or engagement
- Negative FCF margin of -0.6% demonstrates inability to generate positive cash despite operations
- Revenue base is extremely small, indicating weak operating scale and poor asset utilization
- Cash balance is nearly nonexistent and operating cash flow is negative, signaling weak liquidity
- Financial statements look atypical with missing gross profit data and a massive asset base unsupported by revenue, raising quality-of-earnings and balance-sheet reliability concerns
Key Metrics to Watch
- Operating cash flow trend and reconciliation with reported profitability
- Actual revenue growth and composition of asset base
- Insider transaction activity indicating management confidence
- Operating cash flow and ending cash balance
- Revenue growth relative to total assets and equity
Cs Diagnostics Corp.. (CSDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CSDX Profit Margin, ROE & Profitability Analysis
CSDX vs Market Sector: How Cs Diagnostics Corp.. Compares
How Cs Diagnostics Corp.. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cs Diagnostics Corp.. Stock Overvalued? CSDX Valuation Analysis 2026
Based on fundamental analysis, Cs Diagnostics Corp.. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cs Diagnostics Corp.. Balance Sheet: CSDX Debt, Cash & Liquidity
CSDX Revenue Growth, EPS Growth & YoY Performance
CSDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.0K | $4.9K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cs Diagnostics Corp.. Dividends, Buybacks & Capital Allocation
CSDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cs Diagnostics Corp.. (CIK: 0001106861)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CSDX
What is the AI rating for CSDX?
Cs Diagnostics Corp.. (CSDX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CSDX's key strengths?
Claude: Strong reported net profit margin of 34.1%. Zero debt and strong stated stockholders equity position. ChatGPT: Reported operating and net income were positive in the latest period. Balance sheet shows almost no reported liabilities or leverage.
What are the risks of investing in CSDX?
Claude: Severe negative free cash flow of -$528K contradicts profitability claims, indicating cash burn despite reported profits. Extremely limited revenue base of $94.2K indicates minimal business operations or severe business decline. ChatGPT: Revenue base is extremely small, indicating weak operating scale and poor asset utilization. Cash balance is nearly nonexistent and operating cash flow is negative, signaling weak liquidity.
What is CSDX's revenue and growth?
Cs Diagnostics Corp.. reported revenue of $94.2K.
Does CSDX pay dividends?
Cs Diagnostics Corp.. does not currently pay dividends.
Where can I find CSDX SEC filings?
Official SEC filings for Cs Diagnostics Corp.. (CIK: 0001106861) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CSDX's EPS?
Cs Diagnostics Corp.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CSDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cs Diagnostics Corp.. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CSDX stock overvalued or undervalued?
Valuation metrics for CSDX: ROE of 0.0% (sector avg: 15%), net margin of 34.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CSDX stock in 2026?
Our dual AI analysis gives Cs Diagnostics Corp.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CSDX's free cash flow?
Cs Diagnostics Corp..'s operating cash flow is $-528.0, with capital expenditures of N/A. FCF margin is -0.6%.
How does CSDX compare to other Market stocks?
Vs Default sector averages: Net margin 34.1% (avg: 12%), ROE 0.0% (avg: 15%), current ratio N/A (avg: 1.8).